Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lerociclib + Fulvestrant in HR+/HER2- Advanced Breast Cancer
NCT05054751Phase 3Completed
- Sponsor
- Genor Biopharma
- Start
- Sep 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lerociclib in Hormone-Receptor-Positive Breast Cancer, sponsored by Genor Biopharma. Started Sep 2021; status: completed.
02
Drugs
lerociclib
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT05054751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05054751.